Protagonist Therapeutics Inc. has announced a forthcoming conference call and webcast set to occur on Monday, June 30th, at 4:30 pm ET, during which the company will unveil its new oral obesity development candidate. The event will include a presentation of in vitro and pre-clinical proof-of-concept study results related to the candidate. Interested parties can join the webcast through a provided link, and a replay of the presentation will be accessible on Protagonist's Investor Relations webpage following the event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.